Olaparib halts tumour growth in advanced prostate cancer Olaparib, a drug approved for the treatment of women with ovarian cancer who have inherited BRCA mutations, also benefits men with prostate cancer.…
Systematic review suggests mortality benefits of new cholesterol lowering biologics Monoclonal antibodies designed to lower cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) are effective and associated with few major side effects.…
David Reddy: delivery of new anti-malaria drugs to developing countries is vital in fight against the disease David Reddy, Medicines for Malaria Venture’s chief executive officer, discusses developments in the fight against the disease ahead of World Malaria Day on 25 April.…
Combination anti-TB regimen shows bactericidal action, trial indicates A shorter drug regimen for the treatment of tuberculosis is on the horizon, involving moxifloxacin, pretomanid and pyrazinamide.…
Crohn’s disease investigational drug shows promise, phase II trial shows Mongersen, an investigational agent being developed by Celgene, has been tested in Crohn’s disease and researchers have seen clinical remission in some patients.…
AstraZeneca spins out early-stage R&D for antibiotic compoundsAstraZeneca is creating a standalone subsidiary to work exclusively on early-stage antibiotics research and development, the company has announced.…
Immune checkpoint inhibitors bring new hope to cancer patients PD-1 and PD-L1 inhibitors induce a higher response rate across a wider range of tumours than other immunotherapies.…
Q&A: Ensuring vaccine safety is no easy task Patrick LF Zuber, group leader for global vaccine safety at the World Health Organization, talks about vaccine safety, the Ebola vaccine and new vaccines in the pipeline.…
Phase II clinical trials for Ebola vaccine planned for early 2015Experts involved in the organisation of clinical research on Ebola vaccines intend to move to randomised controlled phase II trials in early 2015.…
Potential role for benralizumab in COPD patients with eosinophilia Benralizumab therapy led to a numerical, albeit not statistically significant, improvement in COPD exacerbations and lung function compared with placebo.…
